查看“靶向药”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>靶向治疗</strong>（Targeted Therapy），又称<strong>分子靶向药物</strong>，是现代肿瘤精准医疗（Precision Medicine）的基石。与传统<strong>[[化疗]]</strong>（Chemotherapy）“杀敌一千，自损八百”的细胞毒性机制不同，靶向药利用肿瘤细胞与正常细胞在分子生物学上的差异，针对特定的<strong>“驱动基因”</strong>（如 EGFR, ALK, HER2）或其蛋白产物进行“精确制导”打击。这种治疗模式就像一把“钥匙”只开一把“锁”，能够特异性地阻断肿瘤生长的信号通路，从而诱导癌细胞凋亡，同时最大程度地减少对正常组织的损伤。自 2001 年<strong>[[伊马替尼]]</strong>（格列卫）获批以来，靶向药已将许多曾经的“绝症”（如晚期肺腺癌、慢粒白血病）转化为可长期控制的<strong>慢性病</strong>。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">Targeted Therapy</div>
            <div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Precision Medicine Cornerstone (点击展开)</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 25px; text-align: center; background-color: #f8fafc;">
                <div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);">
                    [[Image:Lock_and_Key_Mechanism.png|100px|锁钥机制示意图]]
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">生物导弹 (Guided Missile)</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">核心策略</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">抑制特定致癌通路</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">主要类型</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">小分子 (TKI, -ib)<br>单克隆抗体 (mAb, -mab)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">必要条件</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;"><strong>[[基因检测]]</strong> (Biomarker)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">代表药物</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">伊马替尼, 奥希替尼<br>曲妥珠单抗</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">主要局限</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;"><strong>[[耐药性]]</strong> (Resistance)<br>靶点稀缺</td>
                </tr>
                 <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">未来形态</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;"><strong>[[ADC]]</strong> (偶联药物)<br>PROTAC</td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">药理机制：锁与钥的匹配</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        靶向药的研发基于对肿瘤分子生物学的深刻理解，主要分为两大阵营：
    </p>

    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>小分子抑制剂 (Small Molecules)：</strong>
            <br>通常以“<strong>-替尼</strong>”(-tinib) 结尾。它们的分子量极小，能够穿透细胞膜进入细胞内部。它们主要结合在胞内激酶域的 ATP 结合口袋上，通过竞争性占位，阻断磷酸基团的转移，从而切断细胞增殖的“电源”信号（如 <strong>[[EGFR-TKI]]</strong>）。</li>
        <li style="margin-bottom: 12px;"><strong>单克隆抗体 (Monoclonal Antibodies)：</strong>
            <br>通常以“<strong>-单抗</strong>”(-mab) 结尾。它们是大分子蛋白质，无法进入细胞，主要结合在细胞表面的受体或循环中的配体上（如 <strong>[[VEGF]]</strong>）。除了阻断信号，抗体还能标记癌细胞，招募免疫系统进行杀伤（ADCC 效应）。</li>
    </ul>

    <h2 style="background: #fff1f2; color: #9f1239; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #9f1239; font-weight: bold;">临床全景：两大阵营的较量</h2>
    <div style="background-color: #fff5f5; border-left: 5px solid #e11d48; padding: 15px 20px; margin: 20px 0; border-radius: 4px;">
        <h3 style="margin-top: 0; color: #be123c; font-size: 1.1em;">没有靶点，就没有靶向</h3>
        <p style="margin-bottom: 0; text-align: justify; font-size: 0.95em; color: #334155;">
            靶向治疗的第一原则是“精准检测”。盲试靶向药不仅无效（如 EGFR 野生型肺癌吃易瑞沙），反而可能因为副作用和延误治疗而有害。
        </p>
    </div>

    <div style="overflow-x: auto; margin: 30px auto; max-width: 95%;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.95em; text-align: left;">
            <tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 20%;">特征</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af; width: 40%;">小分子抑制剂 (TKI)</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #9f1239; width: 40%;">单克隆抗体 (mAb)</th>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">给药方式</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>口服</strong> (Pill)</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>静脉注射</strong> (IV) / 皮下</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">作用位点</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">胞内 (Intracellular)</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">胞外 / 跨膜蛋白</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">半衰期</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">短 (小时级)，需每日服药</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">长 (周级)，2-3周一次</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">穿透性</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">好，新一代药物可穿透<strong>[[血脑屏障]]</strong></td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">差，难以入脑</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">代表药物</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">吉非替尼, 奥希替尼, 洛拉替尼</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">曲妥珠单抗, 贝伐珠单抗, 西妥昔单抗</td>
            </tr>
        </table>
    </div>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>Druker BJ, Talpaz M, Resta DJ, et al. (2001).</strong> <em>Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.</em> <strong>[[New England Journal of Medicine]]</strong>. 2001;344(14):1031-1037.<br>
            <span style="color: #475569;">[划时代突破]：报道了伊马替尼（格列卫）在慢粒白血病中的惊人疗效，标志着人类攻克癌症进入了靶向治疗的新纪元。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>Lynch TJ, Bell DW, Sordella R, et al. (2004).</strong> <em>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.</em> <strong>[[New England Journal of Medicine]]</strong>. 2004;350(21):2129-2139.<br>
            <span style="color: #475569;">[肺癌里程碑]：发现了 EGFR 敏感突变是吉非替尼（易瑞沙）起效的根本原因，开启了实体瘤基于基因分型进行精准治疗的时代。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [3] <strong>Slamon DJ, Leyland-Jones B, Shak S, et al. (2001).</strong> <em>Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.</em> <strong>[[New England Journal of Medicine]]</strong>. 2001;344(11):783-792.<br>
            <span style="color: #475569;">[抗体药物]：证明了曲妥珠单抗（赫赛汀）改变了 HER2 阳性乳腺癌患者的自然病程，确立了单克隆抗体在实体瘤中的治疗地位。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            靶向治疗 · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">对比概念</td>
                <td style="padding: 10px 15px; color: #334155;"><strong>[[化疗]]</strong> (无差别杀伤) • <strong>[[免疫治疗]]</strong> (激活 T 细胞)</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">黄金靶点</td>
                <td style="padding: 10px 15px; color: #334155;">EGFR (肺癌) • HER2 (乳腺癌) • BCR-ABL (白血病) • BRAF</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">耐药模式</td>
                <td style="padding: 10px 15px; color: #334155;">靶点突变 (如 T790M) • 旁路激活 (如 MET 扩增) • 表型转化</td>
            </tr>
            <tr>
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">升级版本</td>
                <td style="padding: 10px 15px; color: #334155;"><strong>[[ADC]]</strong> (抗体偶联药物)：将靶向的“导航”与化疗的“炸药”结合</td>
            </tr>
        </table>
    </div>

</div>